About PharmaIn

About Us

PharmaIN is developing novel treatments for patients with advanced liver cirrhosis and cancer

We are a clinical-stage biopharmaceutical company dedicated to developing first- and best-in-class subcutaneous therapies through peptide engineering.

The patient experience is at the center of everything we do

We are dedicated to improving patient outcomes through innovative therapies that are both effective and easily administered, whether in outpatient or inpatient settings. Our vision is to transform the lives of patients by providing therapeutic solutions that address urgent unmet medical needs. Our cutting-edge, self-injectable medications offer a more convenient and accessible treatment option, particularly for outpatient care, enabling patients to manage their health with greater ease and confidence while also supporting continuity of care during inpatient treatment when needed.

Led by professionals with deep expertise in drug development, biotechnology and healthcare

Our leadership brings a wealth of knowledge and a strong commitment to delivering transformative therapies that not only improve clinical outcomes but also enhance the quality of life for patients.

Leadership Team

Elijah Bolotin, PhD
President, Chief Executive Officer and Board Member

Elijah has over 20 years’ of experience in biopharma science and business, including leading technical roles in Joint Ventures of Endorex Corp with Elan and Novo Nordisk, as well as research at NYU Medical Center. He is inventor and co-inventor of numerous patents, and received his PhD from The Hebrew University, Israel, in biochemistry and pharmaceuticals.

Elijah Bolotin, PhD
President & Chief Executive Officer

Andy Stubbs, PhD
Chief Development Officer

Andy has over 20 years’ experience in the pharmaceutical/biotechnology industry, latterly assuming global-lead roles across Medical Affairs and Clinical Development in oncology. Andy has extensive cell-therapy expertise across four cell therapy platforms and was formerly responsible for launching the world’s first approved cell therapy in the EU. Prior to joining PharmaIN, Andy was global lead for NK cell therapy, clinical development at Sanofi. Before joining industry, Andy concluded a 10-year academic research career as Assistant Professor at the University of Colorado Health Sciences Center. Andy received his PhD in molecular genetics from the Liverpool School of Tropical Medicine, followed by postdoctoral research at Imperial College, London.

Andy Stubbs, PhD
Chief Development Officer

Jenny Martin, RN
VP, Clinical Operations

Jenny Martin has more than 20 years’ experience in establishing and leading clinical operations functions in biotechnology and pharmaceutical clinical development organizations. Most recently, Jenny has led development of Clinical Operation teams in cell therapy for hematology and oncology indications, including T-cell and NK cell therapies at Sanofi, and Juno Therapeutics. Prior to moving into the industry, Jenny worked in Nursing at several hospitals, and managed an active clinical trials group/academic research organization at the University of Washington.

Jenny Martin, RN
VP, Clinical Operations

Lorraine Tracey, PhD
VP, Clinical Development

Dr. Lorraine Tracey is a seasoned pharmaceutical executive with over 20 years’ of experience in clinical development, specializing in oncology, immunotherapy, and advanced drug delivery systems.

Currently serving as Vice President of Clinical Development at PharmaIN, Corp., she leads the strategic advancement of peptide-based therapeutics targeting liver diseases and cancer.

Prior to her current role, Dr. Tracey held pivotal positions at several leading pharmaceutical companies. At Sanofi, she served as Project Lead and Associate Clinical Research Director in Early Oncology Development, where she was instrumental in designing and executing clinical trials for novel cell-based immuno-oncology agents. Her tenure at Kiadis Pharma included roles as Director and Associate Director of Clinical and Medical Affairs, focusing on the development of cell-based immunotherapies. Earlier in her career, Dr. Tracey contributed to clinical development efforts at Ipsen and Teva Pharmaceuticals, gaining valuable experience in oncology and endocrinology therapeutic areas.

Dr. Tracey’s expertise encompasses all phases of clinical development, from early-phase trials to regulatory submissions and post-marketing phase IV trials. She is known for her ability to lead cross-functional teams, develop robust clinical strategies, and navigate complex regulatory environments. Her leadership has been instrumental in advancing multiple therapeutic candidates through the clinical pipeline, ultimately bringing innovative treatments to patients in need. Dr. Tracey holds a Ph.D. in Human Genetics from Trinity College Dublin, where she also earned her B.A. and M.A. degrees. Her academic background provides a strong foundation for her work in translational medicine and clinical research.

Lorraine Tracey, PhD
VP, Clinical Development

Gerardo Castillo, PhD
VP, IP and Grants/Distinguished Scientist

Gerry brings over 20 years’ of comprehensive experience in clinical chemistry, analytical biochemistry, drug development, and drug delivery. He is a highly accomplished grant writer, securing funding for numerous projects, and a prolific author and presenter. As a registered patent agent, he has successfully prosecuted numerous patents and is credited as an inventor on over 100 patents. His professional background includes drug discovery at the University of Washington (in collaboration with Novo Nordisk) and leadership roles as Director of Biochemistry and Drug Discovery Leader at ProteoTech Inc. Notably, Gerry also has experience managing a 350-bed hospital clinical chemistry laboratory in Windsor, Ontario, Canada. He holds a PhD in Clinical Biochemistry from the University of Toronto, an MS in Clinical Chemistry from the University of Windsor, a BS in Biochemistry from the University of Saskatchewan, and is certified in Regulatory Affairs.

Gerardo Castillo, PhD
VP, IP and Grants & Distinguished Scientist

Shawn Iadonato, PhD
Advisor

Biotechnology entrepreneur and executive, Dr. Shawn Iadonato has a distinguished career as a founder and C-level executive (CEO, COO, CSO) for both public and private biotech companies. He has extensive experience in founding, funding, and building innovative businesses with groundbreaking technologies.

Throughout his career, Dr. Iadonato has demonstrated a proven track record in private and public financing, including successfully taking a company public in the US. His expertise spans building and empowering teams, strategic planning, licensing and acquisitions, and product development from discovery through Phase 2 in oncology, inflammation, and infectious diseases.

Notable achievements include his tenure as CEO of Kineta Inc. (2016 – 2024), where he took the company public via a reverse merger and raised approximately $100 million in private and public equity financing. He secured significant partnerships, including a $525 million agreement with Pfizer for immuno-oncology products, a $360 million option and license agreement with Genentech/Roche for neuropathic pain products, and a clinical collaboration with Merck. Additionally, he established a strategic partnership with the Wellcome Trust to develop novel antiviral products for West Africa.

As a founder and CSO at Kineta Inc. from 2008 to 2016, Dr. Iadonato was responsible for all aspects of pipeline development. He successfully completed regulatory submissions in multiple regions and secured $30 million in non-dilutive funding from the NIH and other federal agencies. He is an inventor on more than 35 issued US patents related to drug candidates and platform technologies.

Prior to Kineta, Dr. Iadonato co-founded Illumigen Biosciences Inc., where he raised approximately $20 million in private equity financing and secured a $347 million acquisition by Cubist Pharmaceuticals. He began his career as a Group Leader at the University of Washington Genome Center, leading the high-throughput genome sequencing group. Dr. Iadonato has a PhD in genetics from the University of Washington and a BA in biology from the University of Pennsylvania.

Shawn Iadonato, PhD
Advisor

Board of Directors

Craig Philips
Chairman of the Board

Craig W. Philips is Board Chair of PharmaIN Corporation. He served as the President of Kineta, a Seattle based biotech company focused on immuno-oncology. Mr. Philips has been with Kineta since 2013 in different executive management roles. He has over thirty years’ of pharmaceutical industry experience at both Fortune 500 pharmaceutical and smaller biotech companies.

Previously, Mr. Philips was President at CTI Biopharma a NASDAQ listed clinical and commercial stage oncology company where he led the commercial and development activities in the US and EU. Additionally, he was responsible for business development activities and transactions of several drug programs. Mr. Philips spent over 20 years with leading biopharmaceutical companies and held strategic and operational leadership roles in the US, Asia, Australia and Europe. He has spent the majority of his career in the clinical and commercial development of specialty pharmaceuticals including the launch of four pharmaceutical products which each exceeded $1 billion in sales.

Mr. Philips sits on the board of several private biotech companies, Life Science Washington and was a commercial advisor to the Fred Hutchinson Cancer Research Center and the University of Washington. He was a founder of several specialty pharma biotech companies including CounterX Therapeutics, Abacus Bioscience, and PVP Biologics. He received a BS in Business Administration and an MBA from The Ohio State University.

Craig Philips
Chairman of the Board

Elijah Bolotin, PhD
President, Chief Executive Officer and Board Member

Elijah Bolotin, PhD
Board Member

Mike Shetzline, MD, PhD
Board Member

Dr. Shetzline is Senior Vice President, Chief Medical Officer and Head of Research and Development at Ironwood Pharmaceuticals. Dr. Shetzline is a gastroenterologist and internist, with more than 25 years’ of experience in the biopharmaceutical industry and academia.
Before joining Ironwood, Dr. Shetzline was vice president and head of gastroenterology clinical sciences at Takeda Pharmaceuticals International Co., or Takeda, a global pharmaceutical company, where he led global clinical development for all GI assets from January 2015 to January 2019. Prior to Dr. Shetzline’s role at Takeda, he served as vice president and global head of gastroenterology at Ferring International Pharmascience Center U.S., Inc., from 2012 to January 2015, during which he led Ferring’s clinical development programs in gastroenterology. Before that, Dr. Shetzline was vice president and global program head crossing multiple therapeutic areas and head of translational medicine GI discovery at Novartis Pharmaceuticals AG from 2002 to 2012.
Dr. Shetzline also served as gastroenterology program director and assistant professor of medicine at Duke University Medical Center from 1997 to 2002. Dr. Shetzline has published over 40 full papers and book chapters and acted as a reviewer for a range of medical journals.
Dr. Shetzline earned his M.D. and Ph.D. from The Ohio State University in physiology and medicine. Dr. Shetzline completed his internal medicine residency and fellowship in gastroenterology and served on the faculty as a National Institutes of Health supported physician scientist at Duke University Medical Center.
Dr. Shetzline is a Fellow of the American College of Physicians, the American College of Gastroenterology, and the American Gastroenterological Association and certified by the American Board of Internal Medicine.

Mike Shetzline, MD, PhD
Board Member